Potocki–Lupski syndrome

From WikiMD's WELLNESSPEDIA

(Redirected from Potocki-Lupski syndrome)


Potocki–Lupski syndrome
Synonyms PTLS
Pronounce N/A
Specialty N/A
Symptoms Developmental delay, intellectual disability, autism spectrum disorder, hypotonia, sleep apnea
Complications N/A
Onset Infancy
Duration Lifelong
Types
Causes Genetic mutation
Risks
Diagnosis Genetic testing, clinical evaluation
Differential diagnosis Smith–Magenis syndrome, Williams syndrome
Prevention
Treatment Supportive care, speech therapy, occupational therapy
Medication
Prognosis Variable
Frequency 1 in 25,000
Deaths


Potocki–Lupski syndrome (PTLS) is a rare genetic disorder characterized by the duplication of a small segment of chromosome 17p11.2. This condition was first described by Dr. Lorraine Potocki and Dr. James R. Lupski in 2000. PTLS is associated with a variety of clinical features, including developmental delay, intellectual disability, and distinctive facial features.

Clinical Features[edit]

Individuals with Potocki–Lupski syndrome often exhibit a range of clinical features, which can vary in severity. Common characteristics include:

Genetics[edit]

Potocki–Lupski syndrome is caused by a duplication of a segment of chromosome 17p11.2. This duplication includes the RAI1 gene, which is believed to play a significant role in the development of the syndrome. The duplication can occur de novo (new mutation) or be inherited from a parent with a balanced translocation.

Diagnosis[edit]

Diagnosis of PTLS is typically made through genetic testing, such as chromosomal microarray analysis or fluorescence in situ hybridization (FISH). These tests can identify the duplication of the 17p11.2 region.

Management[edit]

There is no cure for Potocki–Lupski syndrome, and treatment is focused on managing the symptoms and improving the quality of life for affected individuals. Management strategies may include:

  • Early intervention programs for developmental delays
  • Special education services
  • Speech, occupational, and physical therapy
  • Treatment for sleep apnea, such as continuous positive airway pressure (CPAP) therapy
  • Regular monitoring and treatment of congenital heart defects

Epidemiology[edit]

Potocki–Lupski syndrome is a rare condition, with an estimated prevalence of 1 in 25,000 to 1 in 50,000 live births. Due to its rarity, it is often underdiagnosed or misdiagnosed.

See Also[edit]

References[edit]

External Links[edit]

-

This article is a stub related to genetics. You can help WikiMD by expanding it!


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.